Skip to content

Age and Refraction in Predicting Myopia Progression in COVID-19

The Effect of Age and Refraction in Predicting Myopia Progression With Risk Under COVID-19 in a 3-year Follow-up of a Chinese Cohort

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05305274
Enrollment
34400
Registered
2022-03-31
Start date
2019-10-01
Completion date
2021-12-01
Last updated
2022-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopia, Refraction Error

Brief summary

To determine the longitudinal changes of age and refraction in predicting myopia progression with risk under the coronavirus disease 2019 (COVID-19) pandemic in a 3-year follow-up of a Chinese cohort.

Detailed description

This was part of the large-scale Tianjin Eye Study, a population-based cohort study that longitudinally investigates the relationship between the age, refraction, and development of childhood RE in Tianjin, China.

Interventions

OTHERscreening

This study included 34,400 students, as part of the Tianjin Eye Study who performed a 3-year follow-up from 2019 to 2021. All participants underwent yearly noncycloplegic refraction and ocular examinations. Time-related changes in sphere, cylinder, and spherical equivalent (SE) measurements in both sexes were analyzed.

Sponsors

Tianjin Eye Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
6 Years to 15 Years
Healthy volunteers
Yes

Inclusion criteria

* no concurrent eye disease; * age 6-15 years.

Exclusion criteria

* significant systemic illnesses * ocular conditions that could affect the corneal curvature, including congenital corneal diseases, * pterygium, keratoconus, other corneal degeneration or dystrophy conditions, * media opacity, uveitis, glaucoma * a history of intraocular surgery, refractive surgery, * neurologic or retinal diseases, current corneal refractive therapy (ortho-K), * low-dose atropine therapy for myopia control

Design outcomes

Primary

MeasureTime frameDescription
changes of spherechange from baseline at 36 monthschanges of sphere
changes of cylinderchange from baseline at 36 monthschanges of cylinder
changes of spherical equivalentchange from baseline at 36 monthschanges of spherical equivalent
changes and distribution of visual acuitychange from baseline at 36 monthschanges and distribution of visual acuity

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026